We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: precision medicine
MedXY News
EnglishTag

precision medicine

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Can We Predict Who Benefits? Baseline Insulin Secretion as a Gatekeeper for Abatacept Efficacy in Stage 1 T1D
Diabetes & EndocrinologyAbataceptinsulin secretion

Can We Predict Who Benefits? Baseline Insulin Secretion as a Gatekeeper for Abatacept Efficacy in Stage 1 T1D

By MedXY|Feb 4, 2026

A post-hoc analysis demonstrates that baseline insulin secretion identifies responders to abatacept in Stage 1 T1D. High-secretors experienced a 15.8-month delay in disease progression and a 54% reduction in risk, providing the first eviden

Precision Medicine Outperforms Standard Albuminuria Thresholds for SGLT2 Inhibitor Selection in Type 2 Diabetes
Diabetes & EndocrinologyDiabetic Nephropathyprecision medicine
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

Precision Medicine Outperforms Standard Albuminuria Thresholds for SGLT2 Inhibitor Selection in Type 2 Diabetes

By MedXY|Feb 3, 2026

A new precision medicine model identifies high-benefit patients for SGLT2 inhibitor treatment even when albumin levels appear normal, potentially preventing 10% more kidney failure events than current guidelines that rely solely on albuminu

Precision Immunotherapy in Pneumonia: Presepsin-Guided Anakinra Significantly Reduces Organ Dysfunction and Mortality
Critical CareAnakinrapneumonia

Precision Immunotherapy in Pneumonia: Presepsin-Guided Anakinra Significantly Reduces Organ Dysfunction and Mortality

By MedXY|Jan 30, 2026

The Phase IIa INSPIRE trial demonstrates that early administration of anakinra, guided by the presepsin biomarker, reduces the risk of organ dysfunction by 30% and significantly improves 90-day survival in hospitalized pneumonia patients, m

Activating EGFR L858R Variants Linked to Syndromic Generalized Acanthosis Nigricans and Pulmonary Risk: A New Clinical Entity
DermatologyEGFR mutationprecision medicine

Activating EGFR L858R Variants Linked to Syndromic Generalized Acanthosis Nigricans and Pulmonary Risk: A New Clinical Entity

By MedXY|Jan 27, 2026

This study identifies activating EGFR L858R variants as the genetic basis for a syndrome featuring generalized acanthosis nigricans and lung nodules, highlighting the efficacy of EGFR inhibitors in treating both cutaneous and systemic manif

Sepsis Subtypes Are Fluid: How ‘Fuzzy’ Classification Explains Treatment Variability and Patient Trajectories
Critical CareClinical Trajectoriescritical care

Sepsis Subtypes Are Fluid: How ‘Fuzzy’ Classification Explains Treatment Variability and Patient Trajectories

By MedXY|Jan 26, 2026

A large-scale study of 35,691 sepsis patients reveals that clinical subtypes are highly dynamic, with 82% of patients changing categories within 48 hours. This classification uncertainty significantly impacts treatment response and long-ter

Beyond the Scalpel: How ctDNA Blood Tests are Revolutionizing Head and Neck Cancer Monitoring
newsctDNAhead and neck cancer

Beyond the Scalpel: How ctDNA Blood Tests are Revolutionizing Head and Neck Cancer Monitoring

By MedXY|Jan 25, 2026

A new study reveals that ‘tumor-informed’ blood tests can detect recurring head and neck cancer months before traditional scans, offering a critical window for intervention in high-risk patients.

Genetic Risk Profile Predicts Stroke Prevention Benefit From Continuous Atrial Fibrillation Screening: A Secondary Analysis of the LOOP Study
Cardiologyatrial fibrillationpolygenic risk score

Genetic Risk Profile Predicts Stroke Prevention Benefit From Continuous Atrial Fibrillation Screening: A Secondary Analysis of the LOOP Study

By MedXY|Jan 22, 2026

A secondary analysis of the LOOP study demonstrates that continuous ECG screening with implantable loop recorders significantly reduces stroke and systemic embolism in individuals with high genetic risk for atrial fibrillation, while potent

Precision Lead Placement: How 4D Phenomics Digital Heart Models are Revolutionizing Cardiac Resynchronization Therapy
CardiologyCardiac Resynchronization TherapyCMR

Precision Lead Placement: How 4D Phenomics Digital Heart Models are Revolutionizing Cardiac Resynchronization Therapy

By MedXY|Jan 21, 2026

The MAPIT-CRT trial demonstrates that using 4D cardiac MRI-generated digital heart models to guide lead placement significantly improves LVEF in heart failure patients compared to standard techniques, offering a safe and feasible precision

Opportunistic Genomic Screening for Familial Hypercholesterolemia: Does Genetic Feedback Drive Clinical Change?
CardiologyCardiologyFamilial Hypercholesterolaemia

Opportunistic Genomic Screening for Familial Hypercholesterolemia: Does Genetic Feedback Drive Clinical Change?

By MedXY|Jan 16, 2026

This randomized clinical trial investigates whether returning opportunistic genomic results for familial hypercholesterolemia to veterans impacts LDL-C levels. While the primary endpoint missed statistical significance, the findings suggest

Model-Based ATG Dosing Successfully Accelerates CD4+ Reconstitution in CD34+ Selected Allogeneic HCT
Hematology-Oncologyantithymocyte globulinhematopoietic cell transplantation

Model-Based ATG Dosing Successfully Accelerates CD4+ Reconstitution in CD34+ Selected Allogeneic HCT

By MedXY|Jan 13, 2026

A Phase 2 study demonstrates that pharmacokinetic model-based ATG dosing significantly enhances CD4+ T-cell reconstitution in patients undergoing CD34+ selected hematopoietic cell transplantation, reaching primary endpoints in 70% of partic

Advances in Head and Neck Cancer: How Pre-Surgical Immunotherapy is Transforming Patient Outcomes
newsHNSCCimmunotherapy

Advances in Head and Neck Cancer: How Pre-Surgical Immunotherapy is Transforming Patient Outcomes

By MedXY|Jan 13, 2026

A Phase II clinical trial demonstrates that combining tislelizumab with neoadjuvant chemotherapy significantly improves pathological response rates and organ preservation in patients with locally advanced head and neck squamous cell carcino

THAG Regimen Shows High Efficacy as Conversion Therapy for Pancreatic Cancer: New Phase II Trial Results
Gastroenterologyimmunotherapyneoadjuvant therapy

THAG Regimen Shows High Efficacy as Conversion Therapy for Pancreatic Cancer: New Phase II Trial Results

By MedXY|Jan 13, 2026

A Phase II trial demonstrates that the THAG regimen—combining immunotherapy, radiotherapy, and chemotherapy—significantly improves R0 resection rates and survival in patients with BRPC and LAPC, supported by IL-6 and ctDNA biomarker insight

PET/CT-Guided Discontinuation of Immunotherapy in Metastatic Lung Cancer: A Paradigm Shift Toward Precision De-escalation
newsimmunotherapylung cancer

PET/CT-Guided Discontinuation of Immunotherapy in Metastatic Lung Cancer: A Paradigm Shift Toward Precision De-escalation

By MedXY|Jan 10, 2026

A landmark study from the nNGM reveals that PET/CT-guided discontinuation of immunotherapy in long-term lung cancer responders significantly improves survival and identifies second primary cancers, challenging the current practice of indefi

AXL: The Double-Edged Sword in Colorectal Cancer Treatment
Gastroenterologycolorectal cancerimmunotherapy

AXL: The Double-Edged Sword in Colorectal Cancer Treatment

By MedXY|Jan 9, 2026

Researchers have identified AXL expression as a critical biomarker in colorectal cancer. While it usually signals treatment resistance, a new study reveals that AXL-high tumors with KRAS mutations respond significantly better to immunothera

Beyond Detection: How ctDNA Dynamics Predict Treatment Success in Advanced Breast Cancer
newsadvanced breast cancerctDNA

Beyond Detection: How ctDNA Dynamics Predict Treatment Success in Advanced Breast Cancer

By MedXY|Jan 8, 2026

The plasmaMATCH trial establishes ctDNA testing as a highly accurate tool for directing targeted therapies in advanced breast cancer. New data reveal that baseline ctDNA levels and early on-treatment dynamics serve as powerful prognostic ma

Rethinking the Standard: Is a Chemotherapy-Free Future Possible for HER2-Enriched Breast Cancer?
newsbreast cancerHER2-positive

Rethinking the Standard: Is a Chemotherapy-Free Future Possible for HER2-Enriched Breast Cancer?

By MedXY|Jan 8, 2026

The WSG-KEYRICHED-1 trial investigates a chemotherapy-free regimen for HER2-enriched early breast cancer, showing that 47% of patients achieved a pathological complete response using only immunotherapy and dual HER2 blockade.

Beyond HbA1c: How Diabetes Subtyping Predicts Comorbidities and Mortality Over 14 Years
Cardiologycardiovascular riskNephropathy

Beyond HbA1c: How Diabetes Subtyping Predicts Comorbidities and Mortality Over 14 Years

By MedXY|Jan 7, 2026

A landmark Swedish cohort study demonstrates that diabetes subgroups, particularly those characterized by insulin resistance and deficiency, carry significantly higher risks for end-organ damage and cardiovascular mortality than previously

Age and Sex Redefine the Amyloid-to-Tau Transition: Establishing Patient-Centered PET Thresholds for Alzheimer’s Disease
NeurologyAlzheimer's diseaseprecision medicine

Age and Sex Redefine the Amyloid-to-Tau Transition: Establishing Patient-Centered PET Thresholds for Alzheimer’s Disease

By MedXY|Jan 6, 2026

This study establishes patient-centered amyloid PET thresholds for tauopathy onset, revealing that age and sex significantly influence the transition from amyloidosis to tau accumulation. These personalized cut-offs better predict cognitive

The Evolving Genetic Landscape of Parkinson’s Disease: Global Prevalence, Phenotypic Correlations, and the Precision Medicine Imperative
Clinical UpdatesGBA1遺伝学的検査

The Evolving Genetic Landscape of Parkinson’s Disease: Global Prevalence, Phenotypic Correlations, and the Precision Medicine Imperative

By MedXY|Dec 31, 2025

This review synthesizes recent large-scale genomic evidence (ROPAD, PD GENEration, MDSGene) to outline the diagnostic yield, ethnic variations, and genotype-phenotype correlations in Parkinson’s disease, emphasizing the transition toward un

Multiomics Outperform Phenotype in Predicting Post-Diet Weight Regain and Body Composition Dynamics
Diabetes & Endocrinologygut microbiomeMultiomics

Multiomics Outperform Phenotype in Predicting Post-Diet Weight Regain and Body Composition Dynamics

By MedXY|Dec 31, 2025

A post hoc analysis of the LEAN-TIME trial reveals that integrating gut microbiome and metabolomic data with clinical phenotypes significantly improves the prediction of weight loss and regain, offering a framework for precision weight mana

Prev
2 / 3
123
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities